Recent NGS and immunohistochemistry analyses showing the high frequency of the BRAF V600E mutation in patients with ameloblastoma have implicated the involvement of the RAS‐MAPK pathway in the pathogenesis of ameloblastoma.7, 8 However, to date, global gene expression profiles in ameloblastoma remain poorly understood. Here, BRAF is linked to ameloblastoma.